the Lagrange multiplier test. However when we did this there was no significant result forthe ancillary parameter (p = 0.080). We therefore concluded that overdispersion may notbe problem for the Poisson regression model we used. Thus we presented our resultsusing the Poisson regression as shown in the paper.
Results
Inflammatory Marker Change at (Sampled) ExacerbationsThere were 129 sampled exacerbations (87 on placebo and 42 on macrolide) of which 56(35 on placebo; 21 macrolide) were first exacerbations and the remainder were repeatedexacerbations in the same patients. Linear mixed models analysis showed that there was nodifference in estimated marginal means in FEV1, sputum IL6 or sputum IL8 betweenbaseline and first exacerbation, p > 0.05 in all cases. However baseline vs. first exacerbation(N = 56) mean (SE) serum CRP was 7.5(0.7) mg/L (baseline) vs. 19.0 (4.0) mg/l (firstexacerbation), p = 0.004; serum IL6 6.0(1) vs. 12.8 (2.7) pg/ml, p = 0.026; sputum MPO11.2(1.8) ng/ml vs. 22.1(4.9) ng/ml , p = 0.043 respectively. Thus there was elevation inserum CRP, serum IL6 and sputum MPO between baseline and first exacerbation. Howeverthere was no difference between drug and placebo arms in changes n sputum inflammatorymarkers at first exacerbation as shown in Table E1.References1. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920;7: 353–370.
Leave a Comment